Please use this identifier to cite or link to this item:
|Title:||Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics||Authors:||Soong, R.
Methylene tetrahydrofolate reductase
|Issue Date:||Dec-2005||Citation:||Soong, R., Diasio, R.B. (2005-12). Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 6 (8) : 835-847. ScholarBank@NUS Repository. https://doi.org/10.2217/146224184.108.40.2065||Abstract:||In cancer pharmacogenetics (the study of how variability in a single or set of known genes influences drug response) and pharmacogenomics (the study of variability on a genome-wide scale), one of the most important fields of research focuses on the fluoropyrimdines (FPs) and, in particular, 5-fluorouracil (5-FU). After over 40 years of use, FPs remain one of the most commonly used cancer chemotherapy agents and their application includes a wide spectrum of cancer types. FPs also continue to be the baseline component for many new regimens with novel molecular-targeted agents that are being rapidly introduced. Hence, it would seem appropriate that pharmacogenetic/genomic models for optimizing cancer patient management would involve indicators of FP response. In this article, the current trends in FP pharmacogenetics and pharmacogenomics are reviewed based on the advances made to date and the challenges faced in realizing their full potential. © 2005 Future Medicine Ltd.||Source Title:||Pharmacogenomics||URI:||http://scholarbank.nus.edu.sg/handle/10635/113776||ISSN:||14622416||DOI:||10.2217/146224220.127.116.115|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 26, 2022
WEB OF SCIENCETM
checked on Nov 18, 2022
checked on Nov 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.